Evidence map›Paper›PMID 20838918›Full record

ArticleObesity surgery2011

Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days?

Rute Maria Cerqueira, M Conceição Manso, Manuel R Correia, Carolina D Fernandes, Hélder Vilar, Mário Nora, Paulo Martins

Registry-linked trialAbstract readComparative StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05449028 (Helicobacter Pylori Eradication Therapy in Portugal), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05449028 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes

TypeinterventionalSponsorUnidade Local de Saúde de Coimbra, EPERan2022 to 2024Enrolled230ConditionsHelicobacter Pylori, Gut Microbiota, ImmunologyArmsH. pylori eradication scheme A, H. pylori eradication scheme B, H. pylori eradication scheme C, H. pylori eradication scheme D, H. pylori eradication scheme E
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Optimum duration of regimens for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2013
    Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rute Maria CerqueiraGastroenterology, S. Sebastião Hospital, Santa Maria Feira, Portugal. rcerqueira@hospitalfeira.min-saude.pt
M Conceição Manso
Manuel R Correia
Carolina D Fernandes
Hélder Vilar
Mário Nora
Paulo Martins
Hospital de São Sebastião · PTFernando Pessoa University · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe high prevalence of Helicobacter pylori (HP) in our obese population undergoing Roux-en-Y bypass gastric surgery (69.4%) and the concern that it may exacerbate postoperative foregut symptoms and increase gastric cancer risk led us to adopt a policy of HP systematic eradication in this group of patients. Our aim, in obese patients undergoing bypass gastric surgery, was to compare effectivity of 7- and 14-days clarithromycin-based triple therapy as the first-line treatment for HP eradication.

methodsThree hundred seventy-three patients [mean age 41.2 ± 10.3 years; 313 women (83.9%)] were HP positive determined by histology or urea breath test. In 2005, 94 patients (Group A) were treated with a 7-days triple therapy-proton pump inhibitor (PPI) b.i.d., clarithromycin (CL) 500 mg b.i.d., and amoxicillin (AMX) 1,000 mg b.i.d. Since 2006, 279 patients (Group B) were treated with a similar 14-days drug regimen-PPI b.i.d., CL 500 mg b.i.d., and AMX 1,000 mg b.i.d. Posttreatment HP status was assessed by C13 urea breath test 4-6 weeks after the end of therapy.

resultsThe eradication rates were 67.0% (Group A) and 79.9% (Group B). The eradication rate achieved with 14-days triple therapy was significantly higher than with 7-days triple therapy (OR = 1.96; 95% CI: 1.16-3.30; p = 0.016).

conclusionsA 14-days triple therapy is more effective than 7-days triple therapy suggesting this regimen should be the first-line therapy for HP eradication in Portuguese obese patients undergoing bypass gastric surgery.

Indexed as

Gastric BypassHelicobacter pyloriAdultAmoxicillinAnti-Bacterial AgentsClarithromycinDrug Administration ScheduleDrug Therapy, CombinationFemaleHelicobacter InfectionsHumansMaleMiddle AgedObesity, MorbidProton Pump InhibitorsRetrospective StudiesAmoxicillinAnti-Bacterial AgentsClarithromycinProton Pump Inhibitors

Identifiers

PMID20838918
OpenAlexW2032887020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.